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Drug use during pregnancy is sometimes unavoidable, especially in chronicAbstract
inflammatory diseases such as rheumatoid arthritis (RA). The use of disease-
modifying antirheumatic drugs (DMARDs) often starts in the early stage of RA;
therefore, women of reproductive age are at risk for exposure to a DMARD at
time of conception as well as during pregnancy. The aim of this paper was to
review recent literature about DMARDs used for rheumatic diseases in pregnancy
and to describe the type of study designs and results reported.
Twenty-nine studies; eight on hydroxychloroquine/chloroquine, thirteen on
methotrexate, three on sulfasalazine and six on azathioprine were identified. With
respect to hydroxychloroquine, most studies concluded that it could be safely used
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in systemic lupus erythematosus or RA. The same conclusions were drawn from
the azathioprine studies, but the available evidence is scarce. Although the
evidence regarding the safety of methotrexate during pregnancy is conflicting, a
high rate of pregnancy losses indicates a risk to the fetus. For each individual case
it must be decided whether the benefits outweigh the potential risks. No major
teratogenic effects of sulfasalazine were seen although teratogenic effects still can
not be excluded. For all other DMARDs, the information on their use in pregnan-
cy was limited.
This review underscores the gross absence of data on safety and risks of
DMARD use during conception and pregnancy. While young women use these
drugs in pregnancy, this review stresses the importance of good monitoring and
further research.
A chronic disease requires continual attention on mended these kinds of studies as the best available
behalf of the patient and the attending physician. In evidence for identifying teratogens.
the case of a progressive chronic inflammatory dis- This article reviews the recent literature on the
ease such as rheumatoid arthritis (RA), continuous use of DMARDs in rheumatic diseases in pregnancy
medication is often inevitable. Because of a change and describes the type of study designs employed
in the objective of pharmacotherapy, i.e. to include and the results reported.
disease control as well as symptom control, treat-
A search, using EMBASE, the Cochrane Libraryment with disease-modifying antirheumatic drugs
and MEDLINE, was conducted of original manu-(DMARDs) is commenced in the early stages of
scripts in the medical and pharmacological literaturerheumatic diseases.[1,2] Therefore, women who are at
published in English between 1990 and 2004. Thethe reproductive age and who have RA are at risk for
generic (adalimumab, anakinra, auranofin, sodiumexposure to a DMARD or other antirheumatic drugs
aurothiomalate, aurothioglucose, azathioprine, mer-at the time of conception as well as during pregnan-
captopurine, hydroxychloroquine, ciclosporin,cy. Although many women will experience a spon-
cyclophosphamide, etanercept, infliximab, leflu-taneous remission of their disease during pregnancy,
nomide, methotrexate, penicillamine andand therefore continuation of medication might not
sulfasalazine) or brand names of all DMARDs andbe necessary, the risk of drug exposure during con-
biologicals were used at the start of the search, andception, as well as in the first stage of the pregnancy,
this search was refined with one of the followingremains.
keywords or variations: ‘pregnant’, ‘pregnancy out-For those who do require medication during their
come’, ‘birth defects’, ‘malformations’ and ‘adversepregnancy, clinical decisions considering the moth-
outcome’. In addition, the reference lists of appro-er as well as the child have to be made with respect
priate articles, related books, guidelines and pre-to pharmacotherapy. Ideally, these decisions will be
scribing information were used.based on evidence-based information. However, for
Primarily, the search was restricted to humanobvious reasons, randomised controlled trials
studies describing original data; reviews were there-(RCTs) hardly ever include pregnant women. As a
by excluded. If no information could be found onconsequence, decisions in daily practice with re-
human studies, results from animal studies werespect to the use of DMARDs in pregnancy will be
considered (briefly discussed in this review). Thebased on animal experiments, observation studies in
search was also restricted to the use of monotherapyhumans and expert opinion, rather than analytical
in rheumatic diseases (i.e. RA and systemic lupusepidemiological studies such as case-control sur-
erythematosus [SLE]). Studies describing the use ofveillances or follow-up studies. Mitchell[3] recom-
© 2006 Adis Data Information BV. All rights reserved. Drug Safety 2006; 29 (10)
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Table I. Disease-modifying antirheumatic drugs, their indications, US FDA pregnancy-risk category and dosage regimen in rheumatoid
arthritis (RA)[4,5]
Drug Pregnancy-risk Indications Dosage
categorya
Adalimumab RA 40 mg/wk sc
Anakinra B RA 100 mg/day sc
Auranofin C RA 3mg twice daily
Gold sodium thiomalate C RA 50mg weekly im (for 20 weeks)
Aurothioglucose C RA, JIA, psoriatic arthritis 50mg weekly im
Azathioprine D RA, CD, organ transplantation, chronic 1–2.5 mg/kg/day
active hepatitis
Chloroquine C Malaria prophylaxis, liver amoebiasis, 150–300 mg/day (7–10 weeks),
RA, SLE 100–200mg (maintenance treatment)
Ciclosporin C Prophylaxis after organ transplantation, 2.5 mg/kg (2 doses/day)
psoriasis, RA 3–4 mg/kg/day (maintenance treatment)
Cyclophosphamide D Chronic lymphatic leukaemia, 50–200 mg/day orally
autoimmune diseases such as SLE
Etanercept B RA, polyarticular JIA, psoriatic arthritis 25mg twice weekly
Hydroxychloroquine C Malaria prophylaxis, RA, SLE, DLE, 400 mg/day
photodermatoses
Infliximab C CD, RA, AS 3 mg/kg iv
Leflunomide X RA 100 mg/day (3 days), 10–20 mg/day
(maintenance treatment)
Methotrexate X Cancer, psoriasis, RA 7.5–10 mg/wk or
2.5–5mg thrice weekly
Penicillamine D RA, metal intoxication 150 mg/day (start)
Sulfasalazine B CD, RA, PU, UC 1000mg twice daily, orally
a See table II for definitions.
AS = ankylosing spondylitis; CD = Crohn’s disease; DLE = discoid lupus erythematosus; im = intramuscular; iv = intravenous; JIA =
juvenile idiopathic arthritis; PU = proctitis ulcerosa; RA = rheumatoid arthritis; sc = subcutaneous; SLE = systemic lupus erythematosus; UC
= ulcerative colitis.
antirheumatic drugs in other indications (e.g. azathi- effect on the course of RA, the majority are also
oprine post-transplantation) were not included. labelled for other indications (table I). The dosage
All eligible publications were systematically regimen varies between DMARDs and also per indi-
scored for information on specific study design (e.g. cation; the dose in RA therapy is shown in table I.
case report, cohort study or RCT) and outcome of According to the FDA classification, leflunomide
the pregnancies (e.g. number of live births, birth
and methotrexate (pregnancy-risk category X)defects and miscarriages or abortions). Comments
should not be used in pregnancy.
were noted regarding: (i) the type of birth defect; (ii)
Cyclophosphamide, azathioprine and penicillaminethe indication for which the medication was taken;
are in pregnancy-risk category D, meaning that their(iii) the follow-up time after pregnancy; (iv) the use
use during pregnancy may outweigh the teratogenicof co-medication; (v) the exposure time or period of
risks. Most drugs are in pregnancy-risk category orthe drug; and (vi) miscellaneous findings.
B or C (table II), indicating that adequate and well
controlled studies in pregnant women have either1. General Issues
not been performed or showed no risk. No drug is in
pregnancy-risk category A. Adaliumab is the onlyCurrently, 16 drugs (including four biologicals)
agent which has not yet been assigned a pregnancy-are approved by the US FDA for disease modifica-
tion of RA (table I). In addition to their beneficial risk category.
© 2006 Adis Data Information BV. All rights reserved. Drug Safety 2006; 29 (10)
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the suspicion of oculotoxicity and cochlear toxicity,
but none of them found an increased association of
these specific abnormalities with the use of hydrox-
ychloroquine or chloroquine during pregnancy after
a follow-up time varying from 9 months to 19 years.
Five studies[9-11,13,14] concluded that hydrox-
ychloroquine could be safely used during pregnancy
in the treatment of SLE and advised the continuation
of therapy during pregnancy rather than discontinu-
ation. However, it must be noted that there is no
evidence to suggest any benefit from initiating
hydroxychloroquine therapy during pregnancy.
1.2 Methotrexate
The use of methotrexate during pregnancy is
described primarily in case reports, although a few
studies described an exposed cohort. Kozlowski et
Table II. Pregnancy-risk categories according to the US FDA[6]
Category Criteria
A Adequate and well controlled studies of pregnant
women fail to demonstrate a risk to the fetus during the
first trimester of pregnancy (and there is no evidence of
risk during the later trimesters)
B Animal reproduction studies fail to demonstrate a risk to
the fetus and adequate and well controlled studies of
pregnant women have not been conducted
C Safety in human pregnancy has not been determined,
animal studies are either positive for fetal risk or have
not been conducted, and the drug should not be used
unless the potential benefit outweighs the potential risk
to the fetus
D Positive evidence of human fetal risk based on adverse
reaction data from investigational or marketing
experiences, but the potential benefits from the use of
the drug in pregnant women may be acceptable despite
its potential risks
X Studies in animals or reports of adverse reactions have
indicated that the risk associated with the use of the
drug for pregnant women clearly outweighs any positive
benefit
al.[15] found no congenital anomalies among five
live-born children in a cohort of ten pregnancies, but
Thirty studies were identified in the search: the rate of spontaneous abortions was rather high
hydroxychloroquine/chloroquine (eight studies); (three of ten pregnancies). Østensen et al.[22] re-
methotrexate (13); sulfasalazine (3); azathioprine viewed four cases of methotrexate use during preg-
(6). Hereafter, other DMARDs are only briefly dis- nancy. They found three live-born children without
cussed in this article, because of a lack of informa- congenital malformations, and one woman had a
tion. miscarriage. Lewden et al.[27] described 28
pregnancies exposed to methotrexate and found 19
live births, of which one had minor neonatal anoma-1.1 Hydroxychloroquine
lies, five were elective abortions and four were
spontaneous abortions.The use of hydroxychloroquine and chloroquine
during pregnancy in small doses has shown to be Donnenfeld et al.[17] showed, in a series of case
safe.[7] However, when larger doses are used for the reports, ten healthy live births and four first trimes-
treatment of acute malaria, oculotoxicity and coch- ter spontaneous abortions (it was not reported if an
lear toxicity have been reported.[7] autopsy was performed). The remaining case reports
all reported fetuses with minor or major anoma-Since 1990, several studies have investigated the
lies[18-21,23-26] (table IV) except for Feldkamp andsafety of hydroxychloroquine and chloroquine dur-
Carey[16] who described a healthy live birth. Feld-ing pregnancy (table III), most describing its use in
kamp and Carey[16] considered that a critical periodSLE. One study was performed in a randomised
of exposure to methotrexate (>10mg weekly) existsclinical setting,[11] two studies describe a cohort
at 6–8 weeks after conception.comparing an exposed group to a non-exposed
group.[9,14] The remaining studies[7,8,10,12,13] de- Regarding the high rate of spontaneous abortions
scribed a cohort exposed to hydroxychloroquine or seen in the studies mentioned previously,[15,17,22,27] it
chloroquine without a comparative group. must be noted that methotrexate occasionally is used
None of the studies found an increased risk of as an abortifacient in the management of an ectopic
congenital malformations. Most studies looked in or unwanted pregnancy.[20] The guidelines of the
detail for visual and hearing abnormalities, based on American College of Rheumatology advise a female
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Table III. Disease-modifying antirheumatic drugs and pregnancy: studies of hydroxychloroquine (HCQ) and chloroquine (CQ)
Study Design Pregnancy outcome Comments
(country, year)
Levy et al.[7] Exposed 27 pregnancies: 14 live births, with Birth defects: all children are physically and developmentally normal, with no clinical
(Canada, 1991) cohort to no congenital abnormalities; six evidence of eye or hearing defects
HCQ and CQ induced abortions; four spontaneous Indication: SLE (n = 11), RA (n = 3) or malaria prophylaxis (n = 4)
abortions; three stillbirths Follow-up: between 9mo and 19y (mean 5.3y)
Co-medication: prednisone, aspirin (acetylsalicylic acid), ibuprofen, azathioprine,
phenytoin, levothyroxine sodium and penicillamine
Exposure: only in first trimester
Miscellaneous: more patients were on CQ (n = 16) than on HCQ (n = 8). For 18 women,
representing 21 pregnancies, detailed information was reported; further information for
the six pregnancies with an induced abortion was not available
Buchanan et al.[8] Exposed Eight pregnancies: five live births with Birth defects: none presented fetal malformations
(UK, 1992) cohort to two additional live births with Indication: SLE (n = 8); arthritis (n = 7)
HCQ (from neonatal SLE; one fetal loss Follow-up: a 4-year period for 76 patients; no detailed information on these eight
larger cohort) pregnancies
Co-medication: azathioprine, prednisolone and aspirin
Exposure: mean 20wk (range 1–39); 200 mg/day (n = 6) or 400 mg/day (n = 2)
Miscellaneous: larger cohort included 100 consecutive pregnancies in 76 women, of
which eight received HCQ
Buchanan et al.[9] Controlled Exposed: 32 live births (1 twin); one Birth defects: no evidence of visual disturbance was observed
(UK, 1996) cohort Down’s syndrome; two spontaneous Indication: cutaneous rash (n = 33) arthritis (n = 18) and serositis (n = 1) in SLE (n = 31)
receiving abortions; three stillbirths and DLE (n = 2) patients
HCQ Control: 44 live births, one with an Follow-up: no information
extra finger; four spontaneous Co-medication: azathioprine and prednisolone
abortions; five stillbirths Exposure: mean 24.4mo (antenatal) and 28.4wk (pregnancy); 200 mg/day (n = 22) or
400mg/day (n = 14) at some point during gestation
Miscellaneous: HCQ continuation is probably safe during pregnancy in patients with SLE,
but there is no obvious advantage in commencing treatment
Parke and West[10] Exposed Nine pregnancies: nine live births Birth defects: to date, no visual or hearing abnormalities have been reported and
(USA, 1996) cohort to development appears normal
HCQ Indication: SLE
Follow-up: mean 33mo; routine examinations have not been done in all children
Co-medication: prednisone, subcutaneous heparin and aspirin
Exposure: throughout pregnancy; 200 mg/day or 200mg every other day

































ty 2006; 29 (10)
Table III. Contd
Study Design Pregnancy outcome Comments
(country, year)
Levy et al.[11] Randomised 20 pregnancies Birth defects: clinical examination was normal and no auditory deficit occurred.
(Brazil, 2001) controlled Receiving HCQ: ten live births Examination of eyes was normal in all children
study; HCQ or Receiving PL: nine live births; one Indication: HCQ (eight with SLE; two with DLE); PL (nine with SLE; one with DLE)
PL died after delivery at 25 wks of Follow-up: examination at age 1.5–3 years
gestation Co-medication: prednisone and aspirin
Exposure: mean 11wk (start) to 12wk after delivery
Miscellaneous: HCQ is safe in pregnancy with SLE; final prednisone dosage was
decreased in HCQ recipients and increased in PL recipients
Klinger et al.[12] Exposed 21 pregnancies: 20 live births (one Birth defects: no visual or ophthalmological abnormalities in any of the exposed children
(Canada, 2001) cohort to twin), one with congenital birth defect; Indication: SLE or RA
HCQ (14) or one spontaneous abortion Follow-up: ophthalmological examination at mean 2.8 ± (SD) 2.9y
CQ (7) Co-medication: no information
Exposure: mean: 7.2 ± 2.9mo; 317 ± 109 mg/day (HCQ) and 332 ± 116 mg/day (CQ)
Miscellaneous: recruited through the Mother Risk Programme (Canada); inclusion
criteria: ≥1mo of daily CQ or HCQ during pregnancy
Motta et al.[13] Exposed 35 pregnancies: 35 live births, with Birth defects: no baby had ocular symptoms or complications because of maternal
(Italy, 2002) cohort to no congenital malformations treatment
HCQ Indication: SLE (n = 19); scleroderma (n = 3); undifferentiated CTD (n = 2); mixed CTD
(n = 4); dermatomyositis (n = 1); primary antiphospholipid syndrome (n = 4); and RA (n
= 1)
Follow-up: an ophthalmological assessment was done at birth and again at 1y in 16
infants
Co-medication: no information
Exposure: 200 mg/day for ≥1 year before pregnancy and throughout gestation
Miscellaneous: data seem to confirm safety of HCQ treatment during pregnancy
Costedoat- HCQ cohort Exposed (n = 133): 117 live births, Birth defects: no visual, hearing, growth or developmental abnormalities were reported
Chalumeau et with three malformations; 15 Indication: SLE (n = 69 exposed; n = 41 control); miscellaneous/unclassified CTD (n =
al.[14] (France, spontaneous abortions; one fetal 13/4); primary Sjo¨gren’s syndrome (n = 8/8)
2003) death; no induced abortions Follow-up: mean age 26mo (range 12–108mo)
Control (n = 70): 59 live births, with Co-medication: prednisone (n = 108/56); aspirin (n = 112/54); low molecular weight
four malformations; seven heparin (n = 35/13); azathioprine (n = 2/2); intravenous immunoglobulin (n = 2/0)
spontaneous abortions; two fetal Exposure: HCQ ≥6mo prior to pregnancy and continued throughout gestation; 200mg
deaths; two induced abortions twice daily (n = 122); 200 mg/day (n = 11)
Miscellaneous: findings support preliminary evidence for the safety of HCQ during
pregnancy
CQ = chloroquine; CTD = connective tissue disease; DLE = discoid lupus erythematosus; PL = placebo; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus.
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patient, using methotrexate to wait at least one ovu- effects of were seen, although the risk teratogenic
latory cycle after discontinuation of methotrexate events can not be excluded.
therapy before attempting to conceive because of its
1.4 Azathioprine and Mercaptopurineteratogenic potential.[1]
The evidence regarding safety of methotrexate One case report by Oefferlbauer-Ernst et al.[36]
during pregnancy is conflicting, although a critical showed one healthy child after exposure to azathi-
period and dose for exposure are proposed. The high oprine in utero. Francella et al.[35] studied mer-
rate of pregnancy losses indicates a risk to the fetus captopurine, an active metabolite of azathioprine,
and, therefore, in each individual patient, considera- and found no statistically significant increase in
tion regarding the use of methotrexate before, as major malformations and some other outcomes. The
well as during, pregnancy has to be made. However, authors concluded that before conception, at con-
some situations, such as exposure after the first ception or during pregnancy this drug appeared to be
trimester in a severe case of RA, may lead to the safe. Ramsey-Goldman et al.[32] reported on several
conclusion that the benefits of using methotrexate to immunosuppressive drugs being used before or dur-
control disease activity may outweigh the potential ing pregnancy; azathioprine was the only drug ad-
risks. Although some healthy pregnancies have oc- ministered during pregnancy. Although they found
curred after early methotrexate exposure, recom- that the overall survival of women using immu-
mendations to stop methotrexate as soon as a preg- nosuppressive drugs prior to or during pregnancy
nancy is discovered are in order. Clinical research is encouraging, they questioned their safety and long-
warranted to determine the delay between cessation term mutagenic effects. Heneghan et al.[33] and Al-
of methotrexate and safe conception. stead et al.[31] studied an exposed cohort, selected
from a larger cohort, and concluded that the use of
azathioprine during pregnancy appeared to be gen-1.3 Sulfasalazine
erally safe. Nørga˚rd et al.[34] reported the only study
which showed an increased risk of malformations,A population-based case control study (based on
although this could be confounded by disease activi-22 865 malformed offspring and 38 151 healthy
ty. The above studies are summarised in table VI.controls) by Nørga˚rd et al.[29] showed no increased
prevalence of congenital malformations among chil-
1.5 Miscellaneous Disease-Modifyingdren born to women treated with sulfasalazine dur-
Antirheumatic Drugsing pregnancy. The reported use of sulfasalazine
during pregnancy was low (0.07%). 1.5.1 Biologicals
Ka¨lle´n[30] studied children with orofacial clefting
Adalimunab(n = 1044) extracted from a large birth registry (n =
Information on the effects of adalimumab (ap-576, 873) and observed three cases of sulfasalazine
proved by the FDA in 2003) in human pregnancyuse during pregnancy (risk ratio [RR] = 3.0; 95% CI
were not found during the search. The product leaf-0.62, 8.77). Among the total population, he found
let declared that there was no indication from an515 users of sulfasalazine.
animal study of maternal toxicity, embryo toxicityIn contrast, Koyama et al.[28] described a case of a
or teratogenicity.[37]neonate with holoprosencephaly, born to a woman
with continuous sulfasalazine treatment before and Infliximab
during pregnancy. It was the first case report of this Information from a database maintained by the
type of malformation after sulfasalazine use. manufacturer showed 131 women exposed to inflix-
The above described sulfasalazine studies (sum- imab during pregnancy,[38] and outcome data were
marised in table V) are in accordance with its FDA available for 96 women. Sixty-four pregnancies de-
pregnancy-risk category B; no major teratogenic livered a live-born child, miscarriage occurred in 14
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Table IV. Disease-modifying antirheumatic drugs and pregnancy: studies of methotrexate (MTX)
Study Design Pregnancy outcome Comments
(country, year)
Kozlowski et al.[15] Exposed cohort 10 pregnancies: five live-born infants; Birth defects: none of the children exhibited congenital
(USA, 1990) three spontaneous abortions; two abnormalities
elective abortions Indication: definite or classical adult RA (n = 6);
polyarticular juvenile RA (n = 1); allergic angiitis
(n = 1)
Follow-up: mean 11.5y (range 3.7–16.7y)
Co-medication: aspirin, NSAIDs, HCQ, gold
preparations and cytotoxics
Exposure: 7.5 or 10 mg/wk orally. All patients stopped
MTX within first trimester; one was exposed until 15th
week of gestation
Miscellaneous: data extracted from patients who
unknowingly became pregnant; details gathered by
telephone interview; selection criteria: receiving MTX
from January 1961 to July 1986
Feldkamp and Carey[16] Case report One healthy live birth Birth defects: a healthy full-term male infant was born
(USA, 1993) Indication: RA
Follow-up: examination at age 12wk
Co-medication: ibuprofen, misoprostol, cimetidine or
sucralfate (chronic), cefaclor, oxycodone and aspirin
Exposure: time from conception to discontinuation
of MTX was minimal 3d to maximal 39d gestation;
7.5 mg/wk





































ty 2006; 29 (10)
Table IV. Contd
Study Design Pregnancy outcome Comments
(country, year)
Donnenfeld et al.[17] Case reports 14 pregnancies: ten healthy live births, Birth defects: one child with cavernous haemangioma
(USA, 1994) one with cavernous haemangioma; four Indication: RA (n = 7); cancer (n = 2); bacterial infection
first trimester spontaneous losses (n = 1); psoriasis (n = 1); unknown (n = 3)
Follow-up: no information
Co-medication: aspirin, plaquenil, prednisone,
dactinomycin and other chemotherapeutic agents
Exposure: within 1y of conception or during pregnancy
Miscellaneous: the small number of patients in this
sample precluded any conclusions regarding whether
an association exists between preconceptional MTX
exposure and spontaneous pregnancy loss; data
obtained through questionnaires using data from the
teratogen information services (OTIS and ENTIS)
Buckley et al.[18] Case report One live-birth infant with multiple Birth defects: the congenital abnormalities described
(USA, 1997) congenital anomalies are typically seen with exposure to an antifolate and
include facial, skeletal and cardiac abnormalities
Indication: polyarticular juvenile RA
Follow-up: infant died at age 6mo
Co-medication: folic acid, NSAIDs and gold
preparations
Exposure: total dose of ~100mg over a period of 8wk
Miscellaneous: an autopsy was not performed
Del Campo et al.[19] Case report One live birth with structural anomalies Birth defects: fetal aminopterin/MTX syndrome and
(USA, 1997) typical of maternal MTX exposure developmental delay
Indication: chronic severe psoriasis
Follow-up: 2y and 10mo
Co-medication: none taken
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Table IV. Contd
Study Design Pregnancy outcome Comments
(country, year)
Bawle et al.[20] Case reports Three pregnancies: three live births, all Birth defects: fetal MTX syndrome (case 1); mild
(USA, 1998) with anomalies manifestation of fetal MTX syndrome (cases 2 and 3)
Indication: termination of pregnancy (cases 1 and 3);
cancer (case 2)
Follow-up: 26y (case 1); 9y (case 2); 3.5y (case 3)
Co-medication: fluorouracil and radiation therapy (case
2)
Exposure: 6wk post-conception (case 1); 7.5wk till
28.5wk post-conception (case 2); 11–23 wk post-
conception (case 3)
Miscellaneous: early psychomotor development was
normal (cases 1 and 3); ‘mentally deficient’ to low
‘borderline’ limits of intelligence compared with other
students his age (case 2)
Giannakopoulou et al.[21] Case report One live birth with only minor Birth defects: an inguinal hernia was diagnosed
(Greece, 2000) malformation Indication: cancer
Follow-up: growth and development, up to the 22nd
month, are normal
Co-medication: cyclophosphamide and fluorouracil
Exposure: during first and second trimester
Miscellaneous: no information
Østensen et al.[22] Exposed cohort Four pregnancies: three live births, with Birth defects: children have developed physically and
(Norway, 2000) no congenital malformations; one mentally according to their present age
miscarriage Indication: psoriatic arthritis; juvenile chronic arthritis;
RA
Follow-up: 1mo, 8mo and 5y
Co-medication: naproxen, folic acid (at time of
conception)
Exposure: median 4y; between 5mg and 15mg weekly
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Table IV. Contd
Study Design Pregnancy outcome Comments
(country, year)
Kra¨henmann et al.[23] Case report One terminated pregnancy; fetus had Birth defects: fetus was diagnosed with complete AVSD
(Switzerland, 2002) multiple malformations and left-sided diaphragmatic hernia
Indication: RA
Follow-up: pregnancy was terminated at 19wk
Co-medication: folic acid (irregularly)
Exposure: at wk 4+6d and wk 5+6d of gestation: two
10mg injections
Miscellaneous: no information
Nguyen et al.[24] Case report One terminated pregnancy; fetus had Birth defects: multiple internal and external
(USA, 2002) multiple internal and external malformations
malformations Indication: psoriasis
Follow-up: elected termination at 20wk
Co-medication: sertraline
Exposure: 7.5 mg/day orally for 2d at 3.5wk post-
conception
Miscellaneous: autopsy revealed craniofacial, axial
skeletal, cardiopulmonary and gastrointestinal
abnormalities
Granzow et al.[25] Case report One live birth with an incomplete cleft Birth defects: incomplete cleft palate and associated
(USA, 2003) palate and associated asymmetric asymmetric deformities of the toes on both feet
deformities of the toes on both feet Indication: management of a molar pregnancy
Follow-up: at 38d
Co-medication: no information
Exposure: approximately the 8th wk of gestation
Miscellaneous: no information
Chapa et al.[26] Case report One terminated pregnancy, with fetal Birth defects: absent or markedly shortened long bones;
(USA, 2003) anomalies abnormal positioning of the hands; micrognathia;
echogenic bowel and two-vessel umbilical cord
Indication: failed pregnancy termination
Follow-up: pregnancy termination at 26wk
Co-medication: misoprostol
Exposure: at 6wk; 75mg intramuscular
Miscellaneous: no information
Continued next page
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pregnancies and 18 pregnancies underwent elective
abortion.
Srinivasan[39] reported on an exposed cohort of
27 women exposed to infliximab immediately prior
to or during the first trimester of pregnancy. Data
were available for ten women; six women had live-
born children, of whom one died a few days after
birth, three reported a miscarriage and one under-
went an elective abortion.
Burt et al.[40] reported one case of a woman
receiving infliximab shortly after becoming preg-
nant; a healthy child was born and no neonatal
abnormality was noted.
Chakravarty et al.[41] reported two pregnancies
exposed to infliximab; one healthy baby was born,
and one outcome was not stated.
Etanercept
Exposure to etanercept occurred in 15
pregnancies reported by Chakravarty et al.[41] Six
healthy children were born, four were still pregnant
at the time of the report, one had an elective abortion
and one had a spontaneous abortion.
Anakinra
No information about the use of anakinra in
pregnancy was found in literature. The prescribing
information declared that no effect on early develop-
ment, embryo-fetal development or peri-and postna-
tal development was observed.[42]
1.5.2 Leflunomide
The active metabolite of leflunomide is terato-
genic in rats and rabbits and may cause fetal harm in
humans.[43] Therefore, leflunomide must not be ad-
ministered to pregnant women or women who wish
to become pregnant. A safety update by the manu-
facturer of leflunomide[44] involving 310 exposures
during pregnancy reported 164 cases of which the
outcome was known. Forty-three pregnancies were
terminated, 36 women had miscarriages and 85 en-
ded in live births (seven of whom were born with
congenital malformations).
1.5.3 Ciclosporin
Although ciclosporin is a pregnancy-risk catego-
ry C drug (meaning that animal studies either
showed an adverse effect or have not been conduct-
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ed and that there are no adequate and well controlled ous, both healthy children and children with anoma-
studies in pregnant women), a meta-analysis has lies were born.
been conducted by Bar et al.[45] The authors con-
cluded that the use of ciclosporin did not appear to 2. Discussion
be a major human teratogen. They found a non-
This review underscores the gross absence ofsignificant odds ratio for malformations of 3.83
data on the safety and risks of DMARD use during(95% CI 0.75, 19.6).
conception and pregnancy. Regulatory authorities,
scientific societies and rheumatologists and other1.5.4 Cyclophosphamide
specialists are obliged to dissuade the continuationSince 1990, only a few cases have been reported
of most DMARDs if pregnancy is desired. Never-on the use of cyclophosphamide during pregnan-
theless, RA patients do become pregnant and some-cy.[46-48] Cyclophosphamide is considered to be tera-
times continue drug use of DMARDs.togenic and is classified as D in the pregnancy-risk
Since 1990, a limited number of studies oncategory. Two cases reported a live-born child,[46,48]
DMARD use during pregnancy were found. Apartone case reported a child who died 12 days after
from two large case-control studies (22 865 cases vsbirth and was diagnosed with a pattern of malforma-
38 151 controls[29] and 1044 cases vs 576 873 con-tions referred to as cyclophosphamide embry-
trols[30]) and one large cohort (19 430 women),[34]opathy[47] and one case reported an unknown out-
most studies are either small cohorts ranging be-come. In addition to their own case report, Vaux et
tween 4 and 515 (exposed) women or case reportsal.[47] give an overview of all cases reported in the
ranging between 1 and 14 cases.literature between 1964 and 2003. In particular, they
According to Mitchell,[3] two main study ap-described craniofacial and limb defects and showed
proaches have been developed, with the purpose ofthat all reported cases had similar patterns of malfor-
identifying teratogens after marketing approval of amations.
drug, i.e. follow-up studies and case-control surveil-
lances. In follow-up studies, small numbers are suf-1.5.5 Gold Preparations
ficient to identify high-risk teratogens. But for drugsNo reports about the use of gold preparations in
which have a moderate or low teratogenic potential,pregnancy could be found after 1990. According to
large numbers of exposed persons are needed, espe-the product leaflets of aurothioglucose,[49] aura-
cially when the outcome is rare. Case-control stud-nofin[50] and sodium aurothiomalate,[51] all showed
ies have more substantial statistical power and areteratogenic effects in animal studies. The product
therefore more appropriate to identify moderate ter-leaflet of aurothioglucose was thought to be terato-
atogenic drugs. Case-control studies can providegenic in early human studies but later studies indi-
safety and risk estimates that become more precisecate that it might not be harmful. (This information
as data accumulate.could not be confirmed by this literature search).
Despite this, gold preparations are not recommend- The results for the use of methotrexate in preg-
ed for use in pregnancy.[49] nancy reconfirm the category X of the FDA cat-
egorisation, stating that the possible risk clearly
1.5.6 Penicillamine outweighs any positive benefit. The advice to wait at
Since 1990, several case reports have been pub- least one ovulatory circle after discontinuation of
lished on the use of penicillamine in human preg- methotrexate before attempting to conceive remains
nancy.[52-61] Penicillamine is in the D pregnancy-risk valid. In contrast to the FDA categorisation, this
category. All reported cases described the use of review suggests that hydroxychloroquine in moder-
penicillamine in Wilson’s disease, an inheritable ate doses can be safely used during pregnancy in the
autosomal recessive disorder of copper accumula- treatment of SLE or RA. However, these conclu-
tion.[56] The results of the case reports are ambigu- sions are based on small exposed cohorts.
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Table V. Disease-modifying antirheumatic drugs and pregnancy: studies of sulfasalazine (SSZ)
Study Study design Pregnancy outcome Comments
(country, year)
Koyama et al.[28] Case report One neonate with holoprosencephaly Birth defects: dysmorphic features: microcephaly; flat nose; median clefts of lip and
(Japan, 1996) palate and hypotelorism
Indication: CD
Follow-up: child died at 6mo
Co-medication: ferostatin; kernac (plant) and protective drug for gastritis or gastric ulcer
Exposure: treatment before and during pregnancy; 3 g/day
Miscellaneous: an autopsy was not undertaken; pregnancy occurred after treatment with
human menopausal gonadotropin and human chorionic gonadotropin and artificial
insemination
Nørga˚rd et al.[29] Case control 22 865 malformed offspring; Birth defects: no significant increased prevalence of selected congenital abnormalities
(Hungary, 2001) (population 38 151 healthy controls. Indication: CD or UC (except one control)
based) Exposed to SSZ: 17 cases; 26 Follow-up: 1980–1996
controls Co-medication: concomitant drug use was not analysed separately because of
insufficient numbers of women without co-medication
Exposure: first, second and third trimester; 4–8 g/day orally
Miscellaneous: based on self-reported use or logbook information; autopsy was
obligatory for all infant deaths and was usual in still-born fetuses during the study period
Ka¨lle´n[30] Case control Population: 576 873 (Medical Birth Birth defects: in Sweden, maternal drug use is not a major contributor to orofacial clefts
(Sweden, 2003) Registry) Indication: UC and CD (for three cases)
Identified orofacial cleft: 1044 Follow-up: July 1995 through December 2001
SSZ exposure in population: 515 Co-medication: glucocorticoids and naproxen (for 1 of 3 cases)
SSZ exposure among orofacial cleft: Exposure: first trimester
three (observed) Miscellaneous: risk ratio (observed/expected) 3.0 (95% CI 0.62, 8.77); orofacial cleft rate
18.1 per 10 000 births (1044/576 873); data were collected prospectively
CD = Crohn’s disease; UC = ulcerative colitis.
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Azathioprine is categorised as a drug that, despite innovative treatment. They concluded that case se-
indications of fetal risks, can be considered during ries and reports can be well received and have
pregnancy if the benefits of therapy outweigh the significant influence on subsequent literature and
potential risks. The results of this review are in line possibly on clinical practice. They reported that the
with this advice and conclude that azathioprine case reports and case series they found in The Lancet
seems to be generally safe in pregnancy. Only one were followed by a clinical trial in 17% and 33% of
large cohort was conducted, which found an in- cases, respectively. Because pregnant women are
creased risk for malformations, which could be con- usually excluded from clinical trials, case reports
founded by disease activity.[34] It must be realised and case series are the first signals in clinical prac-
that for some drugs (e.g. sulfasalazine and azathi- tice of an adverse effect or outcome after exposure
oprine), information is limited to their use in rheu- to a drug. Ideally, these should be followed by a
matic diseases; studies describing the use of these case-control surveillance or follow-up study. This
drugs in other indications may broaden the discus- overview of the literature showed that although
sion, but are not likely to change the conclusions many case reports, case series and small exposed
found in this review. cohorts did function as a signal for a possible ad-
verse outcome, they were almost never followed byMeijer et al.[62] and Hernandez-Diaz et al.[63] de-
a case-control surveillance or follow-up study. Per-scribed the use of folic acid antagonists, but neither
haps more time is needed to collect enough data tostudy reported a protective effect of folic acid when
conduct proper case-control surveillances or largemethotrexate or sulfasalazine is used. Hernandez-
cohort studies.Diaz et al.[63] showed a reduction of the OR of
having an infant with a neural tube defect when This review focused on recent literature, assum-
carbamazepine or trimethoprim, both folic acid an- ing that older information is taken into account by
tagonists, were administered in combination with the construction of the pregnancy-risk categorisa-
folic acid compared with women who received the tion. Recent information on the influence of
drugs without folic acid. DMARDs on pregnancy and pregnancy outcomes is
limited. This might be explained by the focus on theInformation about other DMARDs is even more
use of DMARDs in rheumatic disease and the use oflimited; studies are mostly based on case reports or
the drugs as monotherapy. Another reason might besmall exposed cohorts. A recent study with respect
the timing of the approval for a particular drug onto cyclophosphamide by Clowse et al.[64] showed
the market. Drugs recently approved, such asthat all four pregnancies exposed to
etanercept and infliximab, are used for a selectedcyclophosphamide resulted in first trimester miscar-
group to whom existing therapy is not effectiveriage thus confirming its category D pregnancy-risk
anymore. Clinical trials exclude pregnant women;status.
therefore, it is to be expected that the information onIt must be noted that small studies are not pow-
these drugs after drug approval is limited.
ered to detect any moderate or low risk for birth
None of the studies reported on the relationshipdefects. If, for example, a certain birth defect oc-
between exposure to the drug, genetic variabilitycurred in 1 of 1000 births, a sample size of approxi-
and the effects of these genetic factors. This mightmately 600 can detect approximately a 20-fold or
not have been an issue when these studies werehigher increase of that birth defect. However, none
conducted; however, this will be an important factorof the cohorts in this review had sample sizes >600
in the future and therefore has to be considered.and are by definition too small to detect a small or
moderate increase in the prevalence of specific birth Despite limited information on the influence of
defects. DMARDs in pregnant women with a rheumatic
Albrecht et al.[65] conducted a study evaluating disease, these drugs are used in practice and despite
the impact of case series and case reports describing the advice to avoid pregnancy patients become preg-
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Table VI. Disease-modifying antirheumatic drugs and pregnancy: studies of azathioprine/mercaptopurine (AZA/MP)
Study Design Pregnancy outcome Comments
(country, year)
Alstead et al.[31] Exposed 16 pregnancies: 15 live births (one Birth defects: all alive and well
(UK, 1990) cohort to AZA twin), with no congenital Indication: CD (n = 14) or UC (n = 2)
abnormalities; two terminations Follow-up: 6mo to 16y
Co-medication: prednisolone (n = 12), sulfasalazine (n = 6), mesalazine (n = 1) and
codeine phosphate (n = 1)
Exposure: seven women continued AZA throughout pregnancy; five stopped before 16wk
gestation
Miscellaneous: AZA appears not to be harmful to the fetus in early or late pregnancy in
humans in doses used in IBD
Ramsey-Goldman Exposed Nine pregnancies: eight live births Birth defects: there were no congenital malformations in the infants exposed to AZA
et al.[32] (USA, cohort to AZA (one twin), with no congenital during pregnancy
1993) (from larger malformations; one neonatal death; Indication: SLE
cohort) one miscarriage Follow-up: mean 6.1y (range 1.5–13y)
Co-medication: no information
Exposure: prior to pregnancy (n = 5) and prior, as well as during, pregnancy (n = 9)
Miscellaneous: final study group consisted of 334 women; 14 patients (23 pregnancies)
were exposed before or during pregnancy to AZA (n = 9) or ciclosporin (n = 3) or
methotrexate (n = 1) or combined AZA and ciclosporin (n = 1); only AZA was
administered during pregnancy
Heneghan et Exposed 31 live births, with two abnormalities; Birth defects: Perthes’ disease; severe mental and physical handicap (neither mother
al.[33] (UK, 2001) cohort to AZA, one fetal death (25wk); one fetal received AZA)
prednisolone loss (20wk); one termination; two Indication: AIH
and ciclosporin miscarriages Follow-up: median 10y (range 1.5–16y)
(from larger Co-medication: prednisolone and ciclosporin
cohort) Exposure: (at conception) AZA 1 mg/kg/day (n = 2) or 2 mg/kg/day (n = 4); AZA 1 mg/kg/
day (n = 8) or 2 mg/kg/day (n = 1) plus prednisolone; prednisolone alone (n = 7) and
ciclosporin (n = 1)
Miscellaneous: AZA appeared to be generally safe and without adverse outcomes
Nørga˚rd et al.[34] Cohort AZA Exposed: 11 live births; two Birth defects: aphakia and multiple malformations
(Denmark, 2003) (or MP) malformations (one died). Indication: UC; CD; myasthenia gravis; vasculitis; IgA nephritis; AIH; glomerulonephrtitis;
Control: 19 418 live births; 711 and renal transplant
malformations Follow-up: no information
Co-medication: prednisolone, ciclosporin, ursodeoxycholic acid and antihypertensive
drugs
Exposure: (variable) 30d before conception to third trimester
Miscellaneous: odds ratio for malformation = 6.7 (95% CI 1.4, 32.4); the data indicate an
increased risk of malformations; associations could be confounded by disease activity;
study period was 1 January 1991 to 31 December 2000
Continued next page
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nant while receiving DMARDs. Therefore, we sug-
gest that a good monitoring system for DMARD use
during pregnancy, which reports all pregnancies ir-
respective of pregnancy outcome, could be of great
help to contribute to the research of possible ter-
atogenicity of DMARDs. In addition, it could help
to provide more solid information to patients and
healthcare professionals in RA treatment.
3. Conclusion
In conclusion, this review underscores the gross
absence of data on safety and risks of DMARD use
during conception and pregnancy. Clinicians work-
ing with young patients using DMARDs are obliged
to dissuade the continuation of most DMARDs in
case pregnancy is desired. Nevertheless, this review
shows that RA patients become pregnant and some-
times continue drug use and; therefore, further re-
search on the safety and risks of these drugs during
pregnancy is necessary.
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